Company Filing History:
2 out of 260 
2 out of 16 Years Active: 2022-2025
Title: Innovations of Ok Jae Lim in Cancer Treatment
Introduction
Ok Jae Lim is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of innovative therapeutic agents for cancer treatment. With a total of 2 patents, his work focuses on bispecific antibodies that target specific cancer markers.
Latest Patents
One of his latest patents is titled "Bispecific antibody specifically binding to GPNMB and CD3, and use thereof." This invention discloses a bispecific anti-GPNMB/anti-CD3 antibody that specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B). The bispecific antibody demonstrates high affinity and specificity to both CD3 and GPNMB, which allows it to induce the death of cancer cells expressing GPNMB while inhibiting their proliferation. This makes the bispecific antibody a promising therapeutic agent for cancers that express GPNMB. Another significant patent is "Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same." This invention relates to an anti-CD3 antibody that has high affinity and specificity for CD3, making it effective for cancer prevention or treatment.
Career Highlights
Throughout his career, Ok Jae Lim has worked with reputable organizations, including the Green Cross Corporation and Mogam Institute for Biomedical Research. His experience in these institutions has contributed to his expertise in developing innovative solutions for cancer treatment.
Collaborations
Ok Jae Lim has collaborated with several professionals in his field, including Eun Jung Song and Jong Wha Won. These collaborations have likely enhanced his research and development efforts in creating effective cancer therapies.
Conclusion
Ok Jae Lim's innovative work in the field of cancer treatment through bispecific antibodies showcases his dedication to advancing medical science. His contributions are paving the way for new therapeutic options for patients suffering from cancer.